Gene Biotherapeutics (formerly known as Taxus Cardium Pharmaceuticals and Cardium Therapeutics) is a company that manages a portfolio of medical technologies. It develops Generx, an angiogenic gene therapy product candidate for the treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. The company also provides Excellagen technology platform, a delivery platform for small molecule drugs, proteins, and biologics, as well as a flowable dermal matrix for wound care.